z-logo
Premium
Moesin overexpression is a unique biomarker of adenomyosis
Author(s) -
Ohara Rena,
Michikami Hiroo,
Nakamura Yuko,
Sakata Akiko,
Sakashita Shingo,
Satomi Kaishi,
ShibaIshii Aya,
Kano Junko,
Yoshikawa Hiroyuki,
Noguchi Masayuki
Publication year - 2014
Publication title -
pathology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 74
eISSN - 1440-1827
pISSN - 1320-5463
DOI - 10.1111/pin.12148
Subject(s) - moesin , adenomyosis , biomarker , pathology , medicine , biology , endometriosis , cell , ezrin , biochemistry , cytoskeleton
Adenomyosis is characterized by extension of endometrial glands and stromal cells into the myometrium. Here we proved that ‘moesin’ is a unique biomarker of adenomyosis. We selected two cases of adenomyosis that had been surgically resected and fixed with formalin. Proteins were extracted from the infiltrating adenomyosis lesions and normal endometrium by tissue microdissection. The extracted proteins were examined using a LC‐MS / MS system and the expression profiles of each region were compared. Two hundred and sixty proteins were detected, among which 73 were expressed more in adenomyosis than in normal endometrium. Among these proteins, we focused on overexpression of moesin in adenomyosis. Expression of moesin estimated semiquantitatively using an immunohistochemistry score was higher in adenomyosis than in normal endometrium. In particular, moesin was significanly overexpressed in stromal cells of adenomyosis than in those of normal endometrium. Relative to normal endometrium, moesin was also overexpressed at the RNA level in 9 of 14 cases of adenomyosis and at the protein level in all 14 cases. We also detected activated (phosphorylated) moesin in adenomyosis lesions. The present findings suggest that moesin is characteristically overexpressed and activated in adenomyosis, and that moesin activation may be related to extension of adenomyosis in the myometrium.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here